Clinical trials: Respiratory Symptoms
Pulmonary Disease, Chronic Obstructive
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COPD is a progressive disease characterized by increasing obstruction to airflow and the progressive development of respiratory symptoms including chronic cough, increased sputum production, dyspnea and wheezing.
- Trial name
- NCT03474081
- Testing
- FF/UMEC/VI, Tiotropium, Albuterol/salbutamol
- Where
- 72 sites in United States, Poland and 1 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Covid19
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19
Q-PROTECT is a placebo controlled randomized trial (RCT) to ascertain the efficacy of hydroxychloroquine (HC) alone or, in combination with azithromycin (AZ), in reducing viral load in patients with COVID 19.
- Trial name
- NCT04349592
- Testing
- Hydroxychloroquine, Azithromycin
- Where
- Qatar
- Volunteers
- 456 people
- Sponsor
- Hamad Medical Corporation
Healthy Volunteer, COPD
Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHaler
The study will characterise inspiratory flow parameters across placebo dry powder inhaler Easyhaler (2 inhaler versions) and placebo Spiriva inhalation powder capsule inhaled via HandiHaler in patients with chronic obstructive…
- Trial name
- TIOPIF (NCT04147572)
- Where
- Estonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Upper Respiratory Tract Infection, Nasal Congestion
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
The study is a clinical evaluation of an over the counter (OTC) combination product containing paracetamol (500 mg), dimethindene maleate (1 mg), phenylephrine hydrochloride (10 mg) compared to paracetamol (500 mg) alone in the…
- Conditions
- Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea, Sneezing
- Trial name
- NCT01448057
- Testing
- Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets, Paracetamol (500 mg) tablets
- Where
- 6 sites in Brazil
- Volunteers
- 341 people
- Sponsor
- Novartis
COPD
Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment
The overall objective is to asses the bronchodilator effect of Tiotropium/Salmeterol/Fluticasone combination delivered via Discair® twice daily as compared with original products Seretide Diskus 500 mcg Inhalation Powder twice…
- Trial name
- NCT03395002
- Testing
- Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder, Tiotropium 18 mcg Inhalation Powder, Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 58 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Pulmonary Disease, Chronic Obstructive
Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)
The objective of this NIS is to measure changes in health status including functional status using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to label after approximately 6 weeks in routine…
- Trial name
- NCT03165045
- Testing
- Spiolto® Respimat®
- Where
- 108 sites in Germany
- Volunteers
- 1,351 people
- Sponsor
- Boehringer Ingelheim
Pain, Constipation
A Study to Demonstrate Improvement in Symptoms of Constipation in Subjects That Require Around-the-clock Opioid Pain Killer Therapy
The primary research objective is to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation as measured by the Bowel Function Index (BFI) compared to subjects taking OxyPR tablets alone with cancer…
- Trial name
- NCT01438567
- Testing
- oxycodone/naloxone prolonged release (OXN PR) tablets, oxycodone prolonged release (OxyPR) tablets
- Where
- United Kingdom
- Volunteers
- 270 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Healthy
The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation
The current study will investigate the relative bioavailability of a spray dried dispersion solid dose formulation of PF 06260414 administered as a single oral dose of 30 mg of PF 06260414 relative to a single oral dose of 30 mg…
- Trial name
- NCT02393807
- Testing
- PF 06260414 solid dose formulation, PF-06260414 nanosuspension
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
COPD
Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
The mean objectives are to evaluate the impact of BDP/FF/G fixed combination on health-status and adherence
- Trial name
- NCT03963167
- Testing
- BDP/FF/G fixed combination
- Where
- Italy
- Volunteers
- 661 people
- Sponsor
- Chiesi Italia
Refractory Chronic Cough
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.
- Trial name
- RIVER (NCT05962151)
- Testing
- NAL ER
- Where
- 14 sites in Canada, United Kingdom
- Volunteers
- 66 people
- Sponsor
- Trevi Therapeutics
Obstructive Sleep Apnea, Nasal Congestion
Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure
1. CPAP compliance will be significantly higher in both the heated humidity with Thermosmart™ and the nasal steroid phases compared to the double placebo phase. 2.
- Conditions
- Obstructive Sleep Apnea, Nasal Congestion, Sinus Congestion
- Trial name
- Thermosmart (NCT00665977)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Clayton Sleep Insititute
Asthma
Comparing Efficacy and Safety of Inhaled SNG001 to Placebo
When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the…
- Trial name
- NCT01126177
- Testing
- Interferon beta 1a
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Synairgen Research Ltd.
Covid19, ARDS
Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS
ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute…
- Conditions
- Covid19, ARDS, Hypoxia, Cytokine Storm
- Trial name
- NCT04657458
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC
Ventilator Acquired Pneumonia
Cost Effectiveness Of Linezolid In Central America
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).
- Trial name
- NCT01040585
- Testing
- Linezolid
- Sponsor
- Pfizer
Post-Amputation Pain, Phantom Limb Pain
Electrical Nerve Block for Amputation Pain
The purpose of the clinical trial is to learn whether electrical nerve block via the Altius System is a safe and effective treatment for patients with post-amputation pain.
- Conditions
- Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain, Stump Pain
- Trial name
- NCT02221934
- Testing
- Altius
- Where
- 22 sites in United States
- Volunteers
- 607 people
- Sponsor
- Neuros Medical, Inc.
Post-COVID-19 Condition, Post-COVID Condition
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
- Conditions
- Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID
- Trial name
- NCT07332338
- Testing
- REGENECYTE®
- Where
- 2 sites in United States
- Sponsor
- StemCyte, Inc.
Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease
A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency
The purpose of this study is to evaluate the safety, tolerability, biological activity, and initial efficacy of PM647a, an investigational Prime Editing therapy, in adults and adolescents with Alpha-1 Antitrypsin Deficiency…
- Conditions
- Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, Alpha-1 Antitrypsin Deficiency (AATD), AATD
- Trial name
- PM647a (NCT07887347)
- Testing
- PM647a
- Volunteers
- 54 people
- Sponsor
- Prime Medicine, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
The COPD Patient Management European Trial (COMET)
The goal of the study is to evaluate a Home-Based Disease Management program specifically developed for patients with Gold III/IV COPD.
- Trial name
- COMET (NCT01241526)
- Testing
- Disease Management, Usual site management
- Where
- 34 sites in France, Germany and 2 more
- Volunteers
- 346 people
- Sponsor
- Air Liquide Santé International
Chronic Obstructive Pulmonary Disease (COPD)
A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
- Trial name
- NCT01712516
- Testing
- QVA149, QAB149, NVA237
- Where
- 95 sites in United States, Colombia and 7 more
- Volunteers
- 1,001 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPD
In COPD patients, a distinctive clustering of symptoms in the 3 parts of the day, early morning, day-time and night-time has been observed. These clusters are relevant to shape the health status and to explain the need of care.
- Trial name
- STORICO (NCT03105999)
- Where
- 40 sites in Italy
- Volunteers
- 683 people
- Sponsor
- Laboratori Guidotti S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.